Neurocrine Biosciences, Inc. (NBIX) Earnings Call Transcripts
Neurocrine Biosciences, Inc.'s Latest Earnings Call - June 9, 2026
In the second quarter of fiscal year 2026, Neurocrine Biosciences reported strong revenue growth driven by its key products, INGREZZA, CRENESSITY, and VYKAT XR. The company provided guidance for INGREZZA revenue in the range of $2.7 billion to $2.8 billion, reflecting continued double-digit growth. Management highlighted the successful launch of CRENESSITY, achieving $150 million in quarterly revenue, and VYKAT XR, which generated approximately $100 million in sales, indicating a robust pipeline and strategic acquisitions that could enhance future growth prospects.
Reported metrics
| Metric | Value |
|---|---|
| Total Revenue | $900M (beat) |
| INGREZZA Revenue Guidance | $2.7B - $2.8B (inline) |
| CRENESSITY Revenue | $150M (positive) |
| VYKAT XR Revenue | $100M (positive) |
| Non-GAAP Net Income | $200M (positive) |
| R&D Investment Rate | 30% - 35% (positive) |
Guidance from management
Management maintained revenue guidance for INGREZZA at $2.7 billion to $2.8 billion, indicating confidence in continued growth despite pricing headwinds. They plan to reassess guidance after the first half of the year.
What management said
It's been a tremendous market for us. I think at the time of launch, we expected peak revenue to be $600 million. That just shows you how good people are forecasting. Now we're at $2.7 billion to $2.8 billion of sales, and it's just a reflection of...
Yes, I think the biggest aspect to volume growth is access and ensuring that if a patient is prescribed INGREZZA that they get INGREZZA. So access is something that we invested in last year. We now have coverage at around 70% or so of patients are on Medicare Part D formularies. And we would expect that to be pretty similar when we go into next year. From a financial perspective, how does that translate to revenue do...
What analysts pressed on
Analysts raised questions about the sustainability of growth rates given pricing pressures and the competitive landscape for new products. There were concerns regarding the potential impact of negotiated prices under the IRA next year and how it may affect revenue.
Main topics on the call
- Revenue Growth from Key Products — Neurocrine reported over $900 million in revenue from its three main products, with INGREZZA alone expected to generate $2.7 billion to $2.8 billion this year. Management stated, "It's amazing 9 years after launch that i...
- Successful Launch of CRENESSITY — CRENESSITY achieved $150 million in quarterly revenue, with management noting that they have been able to help about 10% of patients in its first year. The executive emphasized, "We believe it's going to be a great produ...
- Acquisition of VYKAT XR — The acquisition of VYKAT XR was described as a strategic move, adding another rare endocrine product to Neurocrine's portfolio. The executive mentioned, "It was a great acquisition... and had around $100 million of sales...
- Pipeline Development and Future Data — Management highlighted 20 clinical programs, with key Phase III data expected in 2027 for two programs. They stated, "A transformative year on the psych side next year," indicating strong future potential.
Read the full Neurocrine Biosciences, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. (NBIX) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 112 calls on record spanning January 13, 2020 to June 9, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 112 Neurocrine Biosciences, Inc. earnings call transcripts on record, spanning January 13, 2020 to June 9, 2026. Based on this history, Neurocrine Biosciences, Inc. reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- NBIX
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 112
- First call
- January 13, 2020
- Most recent
- June 9, 2026
- Reporting cadence
- quarterly